Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.67 |
| ▸ | KCNJ6 | P48051 | 4/20 | 0.46 |
| ▸ | KCNJ5 | P48544 | 4/20 | 0.46 |
| ▸ | KCNJ3 | P48549 | 4/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27716301 | 0.86 | PPARG (0.58) | PPARGKCNJ6KCNJ5KCNJ3PTGDR2 | |
| SCHEMBL3216249 | 0.85 | PPARG (0.58) | PPARGKCNJ6KCNJ5KCNJ3PTGDR2 | |
| SCHEMBL4613947 | 0.83 | PPARG (0.54) | PPARGKCNJ6KCNJ5KCNJ3PTGDR2 | |
| SCHEMBL3195607 | 0.82 | PPARG (0.66) | PPARGKCNJ6KCNJ5KCNJ3FFAR1 | |
| SCHEMBL3213206 | 0.82 | PPARG (0.52) | PPARGFFAR1PTGDR2 | |
| SCHEMBL3216047 | 0.82 | PPARG (0.56) | PPARGFFAR1PTGDR2 | |
| SCHEMBL3213964 | 0.82 | NPC1 (0.52) | PPARGFFAR1PTGDR2MAPT | |
| SCHEMBL3198995 | 0.81 | PPARG (0.81) | PPARG | |
| SCHEMBL3219559 | 0.81 | PPARG (1.00) | PPARG | |
| SCHEMBL3206869 | 0.80 | PPARG (0.67) | PPARGKCNJ6KCNJ5KCNJ3PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| CN-101282725-A | Therapeutic agent for diabetes | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2008-10-08 | — | — | CN | disclosed |
| EP-1912645-A2 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 31/4885KCNJ6 3589/4885KCNJ5 3431/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 30/4885KCNJ6 3134/4885KCNJ5 2900/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 31/4885KCNJ6 3589/4885KCNJ5 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.